Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Lau

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
BMC Health Services Research|August 17, 2012
Effects of proactive population-based nephrologist oversight on progression of chronic kidney disease: a retrospective control analysisBrian Lee, Marianne Turley, Di Meng, et al.
Oncotarget|October 31, 2015
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivoFrank P Vendetti, Alan Lau, Sandra Schamus, et al.
Lancet (London, England)|August 28, 2015
Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathwayMarwan Kwok, Nicholas Davies, Angelo Agathanggelou, et al.
Nature Cell Biology|April 19, 2005
Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinaseAlan Lau, Karra M Swinbank, Parvin S Ahmed, et al.
Communications Biology|August 25, 2021
Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment responseTudor Petreus, Elaine Cadogan, Gareth Hughes, et al.
Molecular Cancer Therapeutics|March 21, 2013
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancerMichael A Batey, Yan Zhao, Suzanne Kyle, et al.
Mededpublish (2016)|March 15, 2024
A three-year post-graduate Doctorate in Pharmacy course incorporating professional, experiential and research activities: A collaborative innovative approachJanis Vella, Maresca Attard Pizzuto, Nicolette Sammut Bartolo, et al.
Cell Cycle (Georgetown, Tex.)|September 18, 2012
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatmentLenka Oplustilova, Kamila Wolanin, Martin Mistrik, et al.
British Journal of Cancer|August 4, 2020
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer modelsCharles R Dunlop, Yann Wallez, Timothy Isaac Johnson, et al.
Oncogene|April 12, 2018
BRD4 facilitates replication stress-induced DNA damage responseJingwen Zhang, Austin M Dulak, Maureen M Hattersley, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
BMC Health Services Research|August 17, 2012
Effects of proactive population-based nephrologist oversight on progression of chronic kidney disease: a retrospective control analysisBrian Lee, Marianne Turley, Di Meng, et al.
Oncotarget|October 31, 2015
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivoFrank P Vendetti, Alan Lau, Sandra Schamus, et al.
Lancet (London, England)|August 28, 2015
Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathwayMarwan Kwok, Nicholas Davies, Angelo Agathanggelou, et al.
Nature Cell Biology|April 19, 2005
Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinaseAlan Lau, Karra M Swinbank, Parvin S Ahmed, et al.
Communications Biology|August 25, 2021
Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment responseTudor Petreus, Elaine Cadogan, Gareth Hughes, et al.
Molecular Cancer Therapeutics|March 21, 2013
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancerMichael A Batey, Yan Zhao, Suzanne Kyle, et al.
Mededpublish (2016)|March 15, 2024
A three-year post-graduate Doctorate in Pharmacy course incorporating professional, experiential and research activities: A collaborative innovative approachJanis Vella, Maresca Attard Pizzuto, Nicolette Sammut Bartolo, et al.
Cell Cycle (Georgetown, Tex.)|September 18, 2012
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatmentLenka Oplustilova, Kamila Wolanin, Martin Mistrik, et al.
British Journal of Cancer|August 4, 2020
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer modelsCharles R Dunlop, Yann Wallez, Timothy Isaac Johnson, et al.
Oncogene|April 12, 2018
BRD4 facilitates replication stress-induced DNA damage responseJingwen Zhang, Austin M Dulak, Maureen M Hattersley, et al.
Pageof 6